Are you thinking about starting a GLP-1 medication? About 1 in 8 US adults have used GLP-1s to manage diabetes, treat heart disease, or lose weight.  “At this time, there is no other medication like ...

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. On Jan. 13, the FDA ...

GLP-1s are driving demand for smaller portions, due to reducing consumer appetites. Could this lead to smaller pack sizes?

In a new trial, people who switched to the experimental daily GLP-1 pill orforglipron were able to keep off most of the weight they had lost taking Wegovy or Zepbound. People who switched from Wegovy ...

As GLP‑1 drugs transform consumer diets in real time, food companies are racing to build products that nourish, satisfy and ...

The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce. Many drugs offer comparable weight loss. Healthcare companies have ...

The health of state employees and MassHealth members “is on the line,” clinicians and patients warned on Tuesday, due to diminishing coverage for GLP-1 drugs for weight loss. The cries come against a ...

GLP-1 medications have reached a level of household penetration that food and beverage brands can no longer ignore, but the impact on grocery sales is unfolding more gradually than some might expect.

As more people turn to prescription drugs for smaller weight-loss goals, one writer explores the pros and cons.

Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed ...

A comprehensive meta-analysis of 91 clinical trials involving more than 100,000 patients showed no increased risk for suicidal ideation or other psychiatric adverse events with GLP-1 receptor agonist ...